Neflamapimod

Base Information

• Chemical Name: Neflamapimod
• CAS No.: 209410-46-8
• Molecular Formula: C19H9Cl2F2N3OS
• Molecular Weight: 436.26
• Hs Code.: 2933990090
• UNII: TYL52QM320
• DSSTox Substance ID: DTXSID90175115
• Nikkaji Number: J1.365.840D
• Wikidata: Q27089208
• NCI Thesaurus Code: C170207
• Pharos Ligand ID: X888A8WDDQVS
• Metabolomics Workbench ID: 150322
• ChEMBL ID: CHEMBL119385
• Mol file: 209410-46-8.mol

Synonyms:6H-pyrimido(1,6-b)pyridazin-6-one,5-(2,6-dichlorophenyl)-2-(phenylthio)-;VX-745

Chemical Property of Neflamapimod

Chemical Property:

• Vapor Pressure: 2.13E-13mmHg at 25°C
• Melting Point: 261-264 °C
• Refractive Index: 1.692
• Boiling Point: 578.9 °C at 760 mmHg
• PKA: -0.97±0.40(Predicted)
• Flash Point: 303.9 °C
• PSA: 72.56000
• Density: 1.55g/cm³
• LogP: 5.49270
• Storage Temp.: Store at -20°C
• Solubility.: ≥21.8 mg/mL in DMSO; insoluble in H2O; ≥2.1 mg/mL in EtOH with gentle warming and ultrasonic
• XLogP3: 5.1
• Hydrogen Bond Donor Count: 0
• Hydrogen Bond Acceptor Count: 5
• Rotatable Bond Count: 3
• Exact Mass: 434.9811448
• Heavy Atom Count: 28
• Complexity: 762

Purity/Quality:

99.0%Min ^*data from raw suppliers

VX745 ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: C1=CC(=C(C(=C1)Cl)C2=C3C=CC(=NN3C=NC2=O)SC4=C(C=C(C=C4)F)F)Cl
• Recent ClinicalTrials: Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
• Recent EU Clinical Trials: A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of the Oral P38 Alpha Kinase Inhibitor Neflamapimod in Dementia with Lewy Bodies (DLB)
• Description: VX-745 is an inhibitor of p38α MAPK (IC50 = 9 nM). It is selective for p38α over p38β MAPK (Ki = 220 nM) as well as ERK, JNK, and a panel of 50 kinases when used at a concentration of 2 μM. VX-745 inhibits LPS-induced production of IL-1β and TNF-α in isolated human peripheral blood mononuclear cells (PBMCs; IC50s = 45 and 51 nM, respectively). It reduces disease severity in a type II collagen-induced mouse model of arthritis when administered at a dose of 10 mg/kg.
• Uses: VX 745 is a potent and selective inhibitor of p38α mitogen-activated protein (MAP) kinase. VX 745 is a potential anti-inflammatory agents. Studies suggest that VX 745 may be useful in the treatment of Werner syndrome. VX 745 is a potent and selective inhibitor of p38α mitogen-activated protein (MAP) kinase. VX 745 is a potential anti-inflammatory agents. Studies suggest that VX 745 may be useful in the treatment of Werner syndrome.